Xiuwen Wang

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

Baohui Han, Kai Li, Qiming Wang et al. · JAMA Oncology · 2018 · 591 citations · Full text

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial

Zhihao Lü, Junye Wang, Yongqian Shu et al. · BMJ · 2022 · 438 citations · Full text

Wnt/β-catenin signaling regulates cancer stem cells in lung cancer A549 cells

Ying Teng, Xiuwen Wang, Yawei Wang et al. · Biochemical and Biophysical Research Communications · 2010 · 247 citations

Stem Cell Biology, Signaling Pathway, Medicine +10

Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study

Yuankai Shi, Junling Li, Shucai Zhang et al. · PLoS ONE · 2015 · 200 citations · Full text

Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study

Jianming Xu, Lin Shen, Zhiwei Zhou et al. · The Lancet Oncology · 2020 · 182 citations

Medicine, Pathology, Cancer Treatment +5